logo-loader
viewValeo Pharma Inc.

Valeo Pharma sees a strong outlook for the company after releasing third quarter financial numbers

Valeo Pharma (CSE: VPH-OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive Vancouver wth news the company has released their 3rd quarter financial numbers that showed lower revenue numbers but Saviuk shared some of the one time events that led to that and also how the slowdown due to the pandemic affected the company. 

Saviuk also told Proactive some of the key milestones the company has hit including a very successful capital raise. Saviuk also talked about the future of Valeo and what he is very excited about moving forward.

Quick facts: Valeo Pharma Inc.

Price: 1.43 CAD

CSE:VPH
Market: CSE
Market Cap: $83.04 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

2 days, 9 hours ago

2 min read